Results 51 to 60 of about 6,192 (194)
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen +3 more
wiley +1 more source
, 2008 Introduction: to evaluate the impact on the Italian National Health Service (NHS) budget of the recent introduction of the DPP-4 inhibitor vildagliptin in combination treatment for NIDDM patients.
Pradelli, Lorenzo +2 more
core +1 more source
Diabetic Medicine, Volume 43, Issue 6, June 2026.Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye +18 more
wiley +1 more source
International Journal of Nanomedicine, 2019 Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial ...
Lee CH +9 more
doaj
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson +4 more
wiley +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.Initiation of oral semaglutide in patients with T2D in routine clinical practice in Mexico significantly reduces HbA1c and weight and improves satisfaction with treatment. ABSTRACT Background To investigate the oral semaglutide use among Mexican adults with type 2 diabetes.
Guillermo González‐Gálvez +7 more
wiley +1 more source
Voltammetric determination of vildagliptin in a pharmaceutical formulation
, 2018 Purpose: To determine vildagliptin concentration in a pharmaceutical formulation using voltammetric analysis techniques, and optimize the parameters affecting the techniques.Method: Four types of voltammetry techniques, including cyclic voltammetry (CV),
Fadr, Muneer +2 more
core +2 more sources
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.ABSTRACT Aim Adverse events (AEs) detected in tweets and in the FDA Adverse Event Reporting System (FAERS) provide valuable insights into patient experiences with oral hypoglycemic agents including sodium‐glucose transporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP4) inhibitors. This study compared the side effects identified from tweets with those in
Se‐Hoon Oh +2 more
wiley +1 more source
Diabetic Medicine, Volume 43, Issue 5, May 2026.Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens +8 more
wiley +1 more source